- Home
- GHY vs ATAI Comparison
GHY vs ATAI Comparison
Compare GHY & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHY
- ATAI
- Stock Information
- Founded
- GHY 2012
- ATAI 2018
- Country
- GHY United States
- ATAI Germany
- Employees
- GHY N/A
- ATAI N/A
- Industry
- GHY Trusts Except Educational Religious and Charitable
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- GHY Finance
- ATAI Health Care
- Exchange
- GHY Nasdaq
- ATAI Nasdaq
- Market Cap
- GHY 548.8M
- ATAI 444.7M
- IPO Year
- GHY N/A
- ATAI 2021
- Fundamental
- Price
- GHY $13.23
- ATAI $4.66
- Analyst Decision
- GHY
- ATAI Strong Buy
- Analyst Count
- GHY 0
- ATAI 3
- Target Price
- GHY N/A
- ATAI $13.33
- AVG Volume (30 Days)
- GHY 184.8K
- ATAI 5.2M
- Earning Date
- GHY 01-01-0001
- ATAI 08-14-2025
- Dividend Yield
- GHY 10.58%
- ATAI N/A
- EPS Growth
- GHY N/A
- ATAI N/A
- EPS
- GHY N/A
- ATAI N/A
- Revenue
- GHY N/A
- ATAI $2,309,000.00
- Revenue This Year
- GHY N/A
- ATAI $661.36
- Revenue Next Year
- GHY N/A
- ATAI N/A
- P/E Ratio
- GHY N/A
- ATAI N/A
- Revenue Growth
- GHY N/A
- ATAI 510.85
- 52 Week Low
- GHY $10.24
- ATAI $1.03
- 52 Week High
- GHY $11.92
- ATAI $5.34
- Technical
- Relative Strength Index (RSI)
- GHY 44.45
- ATAI 58.92
- Support Level
- GHY $13.31
- ATAI $4.50
- Resistance Level
- GHY $13.43
- ATAI $4.99
- Average True Range (ATR)
- GHY 0.10
- ATAI 0.35
- MACD
- GHY -0.01
- ATAI -0.04
- Stochastic Oscillator
- GHY 13.88
- ATAI 35.87
About GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.